<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04486885</url>
  </required_header>
  <id_info>
    <org_study_id>hj-20-ESCAI</org_study_id>
    <nct_id>NCT04486885</nct_id>
  </id_info>
  <brief_title>European Study of Cerebral Aspergillosis Treated With Isavuconazole</brief_title>
  <acronym>ESCAI</acronym>
  <official_title>European Study of Cerebral Aspergillosis Treated With Isavuconazole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imagine Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imagine Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study clinical context Cerebral aspergillosis (CA) is a rare location of invasive
      aspergillosis (IA), associated with a high morbidity and mortality. Since 2002, voriconazole
      is the recommended first line treatment of invasive aspergillosis (10). More recently,
      isavuconazole appeared to be not less effective than voriconazole in the treatment of
      filamentous IFI, with a better tolerance profile (11).

      We aim to evaluate better the efficacy and the safety of isavuconazole in the treatment of
      cerebral aspergillosis by a descriptive, multicentric, international retrospective cohort
      study.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Outcome of the patients : alive without CA treatment/alive under CA treatment/ deceased.</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Monitoring of isavuconazole : dosage in the sera and in the cerebro-spinal-fluid</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Adverse events under isavuconazole and drug interactions</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cerebral Aspergillosis</condition>
  <condition>Invasive Aspergillosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        40 adult ou pediatric patients, suffering frome cerebral aspergillosis, diagnosed between
        2017 and 2020, and treated by isavuconazole at least 7 days
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Proven or probable cerebral aspergillosis according to the EORTC criteria modified by
             adding diabetes in the host criteria

          -  In child or adult

          -  Treated by isavuconazole at least 7 days

          -  Diagnosed between March 2017 and June 2020

        Exclusion Criteria:

          -  Possible cerebral aspergillosis

          -  isavuconazole treatment for less than 7 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cerebral aspergillosis</keyword>
  <keyword>isavuconazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspergillosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

